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Accepted 10 August 2016Anovelﬂuorescent immunochromatographic assay for the detection of NT-proBNP in human serumhas beende-
veloped. Based on a sandwich-type immunoassay format, analytes in samples were captured by onemonoclonal
antibody labeled with ﬂuorescent protein and “sandwiched” by another monoclonal antibody immobilized on
the nitrocellulosemembrane, the ﬂuorescence and concentration of analytesweremeasured and then calculated
by ﬂuoroanalyzer. The ﬂuorescent protein is a fusion protein and was prepared through the application of
Streptavidin gene SA, β subunit cpcB of Phycocyanin, lyase alr0617, and phycoerythrobilin synthetase gene
ho1, pebA, pebB for covalent binding. It is characterized with higher stability, good solubility in water and it is
not easy to quench ﬂuorescence. Take the advantages of ﬂuorescent protein, the immunochromatographic
assay exhibited a wide linear range for NT-proBNP from 200 pg ml−1 to 26,000 pg ml−1, with a detection limit
of 47 pg ml−1 under optimal conditions. Compared with chemiluminescence immunoassay (CLIA), 131 human
serum samples were analyzed and the correlation coefﬁcient of the developed immunoassay was 0.978. These
results demonstrated that ﬂuorescent immunochromatographic assay is a more rapid, sensitive, speciﬁc method
and could be developed into a platform for more biomarkers determination in clinical practice.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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N-terminal pro-B-type natriuretic peptide (NT-proBNP) is derived
from the precursor peptide, namely proBNP. The proBNP is synthesized
mainly in heart ventricles [1] and is cleaved into active hormone BNP
and inactive N-terminal proBNP (NT-proBNP) [2]. Compared with
BNP, the NT-proBNP contains 76 amino acids and has better stability
in circulating blood. In light of this, it has been widely applied as a bio-
marker of cardiovascular disease [3] and in particular a marker of heart
failure [4,5], coronary artery disease [6,7], chronic kidney disease [8], di-
abetes mellitus and systemic hypertension [9], and holds promise as a
tool for screening of the general population both for the detection of un-
derlying cardiac structural and functional abnormalities as well as the
early detection of potential cardiovascular events [10].
During the past decades, several analytical methods have been
developed for the detection of serum levels of NT-proBNP, including ra-
dioimmunoassay (RIA) [11,12], immunoradiometric assay (IRMA) [13],
the enzyme-linked immunosorbent assay (ELISA) [14] and recently-
developed electrochemiluminescence immunoassay (ECLIA) [15].y Medicine, Nanfang Hospital,
. This is an open access article underWhile ELISA needs more sample volume and a long detection time,
RIA and IRMA have more radionuclide pollution problem and less auto-
mation, ECLIA characterized by high sensitivity, speciﬁcity and easily-
operated automation, still needs high cost, laboratory-oriented large an-
alytical instrument, well-trained personnel sample transportation and
increased waiting time. Therefore, investigating a novel, simple, rapid,
sensitive and speciﬁc method to detect NT-proBNP at an early stage
and to improve the treatment success has garnered considerable
interest.
Recent improvements about methods for detecting the levels of
NT-proBNP have focused on developing point-of-care testing
(POCT) of NT-proBNP to offer rapid, accuracy testing result for patients,
and improve the therapeutic strategies timely. Immunochromatographic
assay is a simple, rapid and user friendly immunoassay which has been
widely used in clinical diagnosis [16–18], food analysis [19,20], environ-
ment monitoring [21]and agriculture [22,23]. The immunosensor of
immunochromatographic assay is based on various labels, e.g., colloidal
gold [24], ﬂuorescent immunoliposomes [25], nanoparticle [26–28],
ﬂuorescent microspheres [29] and quantum dot [30]. Colloidal gold pos-
sesses long-term stability, user-friendly format, a short period of results
obtainment and inexpensive cost, while it is just qualitatively and
shows serious sensitivity limitations. Although other immunosensors
based on ﬂuorescence or electrochemical have brought quantitative
determination to clinical practice, various sensitivity, speciﬁcity, linearthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quantitatively immunochromatographic assay is still imperative in order
to improve accuracy of the testing results for patients.
Herein we ﬁrst report the development of a novel ﬂuorescent
immunochromatographic assay for the sensitive and rapid detection
of NT-proBNP in human serum, plasma and whole blood using
ﬂuorescent-streptavidin fusion protein which has been applied for china
national invention patent (ZL200710030603.6) as an immunosensor.
The ﬂuorescent-streptavidin fusion protein gene sequences comprise
Streptavidin gene SA, β subunit cpcB of Phycocyanin, lyase alr0617,
and phycoerythrobilin synthetase gene ho1, pebA, pebB. And the fusion
protein prepared by genetic engineering recombinant technologies are
used to conjugate to anti-NT-proBNP antibody labeled with biotin for
amplifying signal output. The phycocyanin-streptavidin fusion protein
can emit strong ﬂuorescence with good light absorption properties and
high quantum yield. It has a wide range of excitation and emission in
the visible region of the spectrum. It can be applied to the functional ma-
terial ﬁelds of food, health care andmedicine, in particular to the ﬂuores-
cent probe in the biological and medical molecular monitoring ﬁeld.
Therefore, we choose the fusion protein as the immunosensor and it is
characterizedwith higher stability, goodwater solubility, shorter analysis
time and shows a wider linear range. In this study, a total of 131 human
serum samples were analyzed by our developed immunoassay. Com-
pared with conventional immunoassay, these data showed good correla-
tion. Thus, this assay has signiﬁcant promise to offer a new avenue for
POCT of more future important biomarkers.
2. Materials and methods
2.1. Chemicals and reagents
Biotin, Bovine serum albumin (BSA), dimethylformamide (DMF),
polyvinyl alcohol AH-26, polyglucosan20000, D-trehalose and Tween-
20 were obtained from Sigma-Aldrich. (St. Louis, MO, USA). The anti-
body pairs, namely murine anti-NT-pro BNP mAb 4NT1-15F11 and
grNT1-02, Goat anti-mouse IgG were purchased from Fitzgerald
(North Acton, MA, USA). Nitrocellulose membrane, glass ﬁber mem-
brane, absorbent pad, sample pad and conjugate pad were purchased
from Millipore (Bendford, MA, USA). Fluorescent-streptavidin fusion
proteinwas produced in our laboratory. All solvents and other chemical
were of analytical reagent grade and used as received.
2.2. Apparatus
The test strip fabrication system consists of an R5DDA automatic dis-
penser, a FR-900 sealer, a P2-40 laminator, and the Guillotine cuttingFig. 1. Schematic diagram of the immsystem C-6, which were purchased from Shanghai Hangan Electronic
Technology Co, Ltd. The Multifunctional ﬂuorescence detector 425-406
was obtained from HIDEX (Finland) to collect the ﬂuorescence signal
of the assay on the test strip.
2.3. Labeling of anti-NT-proBNP antibody with biotin
The procedure of anti-NT-proBNP antibody (grNT1-02) coupled
with biotin was described as following. Brieﬂy, the anti-NT-proBNP an-
tibody was diluted in 0.8% NaCl PBS buffer to a concentration of
6.5 mg ml−1 by using a centrifuge tube before labeling. Biotin was dis-
solved in DMF solution to a ﬁnal concentration of 0.01 mol l−1. Then
65 μl of 0.01 mol l−1 biotin was added into 1 ml of 6.5 mg ml−1 anti-
NT-proBNP antibody in a centrifuge tube with shaking 30 s and the re-
action mixture was incubated at 30 °C for 30 min. Afterward, 2.6 μl of
1 mol l−1 NH4Cl was added into the mixture for blocking labeling reac-
tion at 30 °C for 10 min. The excess unreacted NH4Cl and biotin were
eliminated from the mixture by dialysis with 0.8% NaCl PBS buffer
(pH 7.4) at 4 °C for 2 h. The dialysis step was repeated 3 times and
each time the dialysis solution should be changed. Finally, the biotin-
labeled anti-NT-proBNP antibody (6.5 mg ml−1) was stored at−20 °C
before use.
2.4. Preparation of ﬂuorescent protein modiﬁed by streptavidin
The ﬂuorescent protein is a fusion protein and was prepared by ge-
netic engineering recombinant technology. The gene sequences of the
ﬂuorescent protein consist of Streptavidin gene SA, β subunit cpcB of
Phycocyanin, lyase alr0617, and phycoerythrobilin synthetase gene
ho1, pebA, pebB. Speciﬁc forward and reverse primers were designed
to amplify the target fragment. Then the gene fragment of the ﬂuores-
cent proteinwas transferred to plasmid, and the fusion gene that simul-
taneously containing β subunit cpcB of Phycocyanin, Streptavidin and
histag was screened. By expression, identiﬁcation and puriﬁcation of
the fusion protein, the ﬂuorescent protein modiﬁed by streptavidin
was obtained.
2.5. Preparation of the test strip
The test strip consists of six components: the sample application
pad, ﬂuorescent marker conjugation pad, labeled antibody conjugation
pad, nitrocellulose membrane, absorption pad and backing card. The
preparation of the test strip was described as follows. The sample appli-
cation pad (1.5 cm × 30 cm) was made of glass ﬁber and it was ﬁrstly
treated with PBS buffer (0.1 M, pH 7.4) containing 2% polyvinyl alcohol
AH-26, 2% D-trehalose, 1% BSA, 10% Sodium azide and 2% Tween-20 forunochromatographic test strip.
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Fig. 3. Optimization of the marking proportion of biotin and anti-NT-proBNP antibody
grNT1-02 (0.125:1, 0.25:1, 0.5:1, 1:1, 2:1, 4:1).
Fig. 2. Schematic illustration of the principle of ﬂuorescent immunochromatographic assay. (A) Liquid sample containing analytes (NT-proBNP)was added to the sample pad. (B) Analyte
was bound with anti-NT-proBNP antibody (grNT1-02) labeled with biotin and migrated along the other end of the test strip by capillary action. (C) The complex NT-proBNP-anti-NT-
proBNP antibody (grNT1-02)-biotin was conjugated to the ﬂuorescent protein modiﬁed by streptavidin through the streptavidin-biotin ampliﬁcation system. (D) Anti-NT-proBNP
antibody (4NT1-15F11) immobilized on the test line capture the complex NT-proBNP-anti-NT-proBNP antibody (grNT1-02)-biotin-ﬂuorescent protein and form sandwiched
complexes. (E) Some of the analytes continue to ﬂow toward the control line and forms a ﬂuorescent band regardless of the presence or absence of NT-proBNP. Finally, excess analytes
continue to ﬂow into the absorption pad at the end of the strip.
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room temperature. The conjugation pad (1 cm× 30 cm) was alsomade
up of glass ﬁber and it was ﬁrstly pretreated with PBS buffer (0.1 M,
pH 7.4) containing 2% polyvinyl alcohol AH-26, 0.5% Glucan 20000, 2%
D-trehalose, 2% BSA, 10% Sodium azide and 2% Tween-20 for 10 min.
Then it was dried for 15 h at 37 °C and stored in a desiccator at room
temperature. For preparation of ﬂuorescent marker conjugation pad,
the ﬂuorescent marker was diluted to concentration of 1.0 mg ml−1
with PBS buffer (0.1 M, pH 7.4) and dispensed at 3.9 μl cm−1 onto
the pretreated glass ﬁber pad using an automatic dispenser, followed
by being dried for 6 h at 37 °C and then stored at room temperature
in a sealed foil bag. For preparation of labeled antibody conjugation
pad, the biotin labeled antibody grNT1-02 was diluted to concentra-
tion of 0.5 mg ml−1 with PBS buffer (0.1 M, pH 7.4) and dispensed at
3.9 μl cm−1 onto the pretreated glass ﬁber pad using an automatic
dispenser, after drying for 6 h at 37 °C, it was stored at room temper-
ature in a sealed foil bag. The detection zone of the nitrocellulose
membrane involves immobilized goat anti-mouse antibodies as con-
trol line and anti-NT-proBNP antibodies as test line (0.3 and
2 mg ml−1 in 0.1 M PBS buffer, pH 7.4, respectively) dispensed at
1 μl cm−1 using an automatic dispenser. Then the nitrocellulose
membrane was dried for 6 h at 50 °C and stored in a desiccator at
room temperature for using. The absorption pad was stored at
room temperature without any treatment. All of the above parts
were assembled on a plastic adhesive backing card in proper order
as follows. Firstly, ﬁxed the nitrocellulose membrane to the bottom
of the backing card, and then ﬁxed the absorption pad, ﬂuorescent
marker conjugation pad, labeled antibody conjugation pad and the
sample application pad to the top. Finally, the test strip (Fig. 1)with a 4.1 mm width was cut using the Guillotine cutting system C-
6 and assembled into strip cassettes for the following assay.
2.6. Sample preparation
131 serum samples, 50 plasma and 50 whole blood samples were
collected from Nanfang Hospital (Guangdong, China) and stored at
−20 °C until use. The Ethical Committee of Science and Technology De-
partment of the Southern Medical University approved collection of
these samples.
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Fig. 4. Optimization of the concentration of biotin-labeled anti-NT-proBNP antibody (grNT1-02) applied (varied from 0.2 to 1.0 mg ml−1). The NT-proBNP standard samples with three
different concentrations (50, 1500 and 15,000 pgml−1) were detected in this assay by using 1.0 mgml−1 of ﬂuorescent protein, 2.0 mgml−1 of anti-NT-proBNP antibody (4NT1-15F11)
and 0.3 mg ml−1 of goat anti-mouse antibody.
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The immunochromatographic assay on the test strip was performed
as follows: 100 μl of sample was added to the sample application pad,
after 10 min reaction at room temperature, the test strip was inserted
into the multifunctional ﬂuorescence detector, then the ﬂuorescence
signal was measured at the wavelength of 555 nm.3. Results and discussion
3.1. Principle of the immunochromatographic assay
In this study, the basic principle of this method is based on a
sandwich-type immunoassay format. Analytes in samples were cap-
tured by one monoclonal antibody labeled with ﬂuorescent protein
and “sandwiched” by another monoclonal antibody immobilized on
the nitrocellulose membrane, then ﬂuorescence was measured by
ﬂuoroanalyzer and the concentration of analytes could be calculated.
The detailed principle of the proposed immunochromatographic assay
is illustrated in Fig. 2. During the assay, a certain amount of sample con-
taining NT-proBNP was applied onto the sample application pad as
shown in Fig. 2A. Subsequently, NT-proBNP migrated along the porous
membrane by capillary action and then bound to anti-NT-proBNP anti-
body (grNT1-02) labeled with biotin (Fig. 2B). Then, the ternary com-
plex could be conjugated to the ﬂuorescent protein modiﬁed by0.0 0.5 1.0 1.5
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Fig. 5. Optimization of the concentration of ﬂuorescent marking protein applied (varied from 0
(50, 1500 and 15,000 pgml−1) were detected in this assay by using the concentrations of biotin
antibody (4NT1-15F11) 2.0 mg ml−1, and immobilized goat anti-mouse antibody 0.3 mg ml−streptavidin through the streptavidin-biotin ampliﬁcation system
(Fig. 2C). The formed complexes continued to migrate along the mem-
brane to the test zone and were selectively captured by the anti-NT-
proBNP antibody (4NT1-15F11) which were immobilized on the test
zone of the nitrocellulose membrane to form sandwiched complexes
as shown in Fig. 2D. Some of the analytes will continue to ﬂow toward
the control line and form a ﬂuorescent band regardless of the presence
or absence of NT-proBNP (Fig. 2E). Finally, the ﬂuid fraction containing
excess analytes continue to ﬂow into the absorption pad at the end of
the strip. After a complete assay, quantitative analysis was obtained by
reading the ﬂuorescence intensities of the test line with ﬂuoroanalyzer.
The more NT-proBNP in the sample, the more ﬂuorescence conjugates
would bind to the capturing antibodies in the test line, which leads to
the increase of the ﬂuorescence intensity. Therefore, the concentration
of the NT-proBNP could be calculated due to the ﬂuorescence signal is
proportional to the analyte concentrations in the sample. Using this
strategy, a simple, rapid, sensitive and speciﬁc assay has been developed
for the detection of NT-proBNP in the human sample.
3.2. Optimization of the marking proportion of biotin and anti-NT-proBNP
antibody grNT1-02
Optimization of the marking proportion of biotin and anti-NT-
proBNP antibody grNT1-02 (0.125:1, 0.25:1, 0.5:1, 1:1, 2:1, 4:1) was di-
rectly tested using a nitrocellulose membrane coated with excess goat
anti-mouse antibodies. The ﬂuorescence intensity increased with2.0
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-labeled anti-NT-proBNP antibody (grNT1-02) 0.5mgml−1, immobilized anti-NT-proBNP
1, respectively.
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Fig. 7. The standard curve for the ﬂuorescent immunochromatographic assay for the
detection of NT-proBNP under optimized experimental conditions. Fluorescence
intensity and standard deviations were calculated from a set of four measurements. X
axis, represents the concentration of NT-proBNP. Y axis, represents the ﬂuorescence
intensity.
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Fig. 6. Optimization of the reaction time (varied from 3 to 30min). The NT-proBNP standard samples with three different concentrations (50, 1500 and 15,000 pgml−1) were applied in
this assay.
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(Fig. 3). However, if the marking proportion were less than 0.25:1, the
ﬂuorescence intensity tended to reach a maximum. Therefore, the
marking proportion of 0.25:1 was selected as the optimum because sat-
isfactory signal intensity was achieved.
3.3. Optimization of the concentration of biotin-labeled anti-NT-proBNP
antibody grNT1-02
Biotin-labeled anti-NT-proBNP antibody grNT1-02 loaded on the
glass ﬁber by physical absorption were used to capture NT-proBNP in
this sandwich-type immunoassay. Hence, the linear range of this meth-
od was determined mostly by the concentration of biotin-labeled anti-
NT-proBNP antibody grNT1-02. In order to save the cost of materials
and heighten the sensitivity of the assay, the concentration of biotin-
labeled anti-NT-proBNP antibody grNT1-02 was optimized. To ensure
the sensitivity of the proposed method, a nitrocellulose membrane
test stripwas preparedwith 1.0mgml−1 of ﬂuorescent protein concen-
tration, 2.0 mg ml−1 of anti-NT-proBNP antibody 4NT1-15F11 concen-
tration and 0.3 mg ml−1 of goat anti-mouse antibody concentration.
The sensitivity was investigated with concentrations of biotin-labeled
anti-NT-proBNP antibody grNT1-02 (0.2, 0.3, 0.5 and 1.0 mg ml−1)
and three different concentrations (50, 1500 and 15,000 pg ml−1) of
NT-proBNP were added to the test strip to detect the ﬂuorescence sig-
nals. The results were shown in Fig. 4. Under the conditions of high,me-
dium and low concentrations of NT-proBNP, ﬂuorescence intensity
increased as the increasing concentration of biotin-labeled anti-NT-
proBNP antibody grNT1-02, and 0.5 mg ml−1 of biotin-labeled anti-
NT-proBNP antibody grNT1-02 concentration has fulﬁlled the reaction
demands. Therefore, 0.5 mgml−1 of biotin-labeled anti-NT-proBNP an-
tibody grNT1-02 concentrationwas chosen as the optimal working con-
centration for subsequent assays.
3.4. Optimization of the concentration of ﬂuorescent marking protein
Theﬂuorescentmarkingprotein loaded on the glassﬁber byphysical
absorption was used to conjugate with biotin-labeled anti-NT-proBNP
antibody grNT1-02 (the conjugation principle has been illustrated at
Section 3.1) in this assay. The sensitivity of this method for NT-proBNP
was closely related to the concentration of ﬂuorescent marking protein.
Optimization of the concentrations of ﬂuorescent marking protein (0.5,
1.0, 1.5 and 2.0 mg ml−1) was also done using NT-proBNP standard
samples of concentrations of high, medium and low. The assay was car-
ried out on a nitrocellulose membrane test strip which was prepared
with the concentrations of biotin-labeled anti-NT-proBNP antibodygrNT1-02 0.5 mg ml−1, immobilized anti-NT-proBNP antibody 4NT1-
15F11 2.0 mg ml−1, and immobilized goat anti-mouse antibody
0.3 mg ml−1, respectively. As shown in Fig. 5, a higher ﬂuorescence in-
tensity was achieved with the increasing concentration of ﬂuorescent
marking protein and this then remained unchanged with an increase
in the ﬂuorescent marking protein concentration. And 1.0 mg ml−1 of
ﬂuorescent marking protein concentration has met the reaction de-
mands, increasing the concentration of ﬂuorescent marking protein
would enhance the background ﬂuorescence interference, which
might interfere the judgement of results. Therefore, 1.0 mg ml−1 of
ﬂuorescent marking protein concentration was selected as the optimal
concentration for the following experiments.3.5. Optimization of the reaction time
It iswell known that the reaction time can dramatically inﬂuence the
immunoassay sensitivity and the immunoreaction between antigen and
antibody. In this assay, the effect of reaction times was investigated at 3,
5, 7, 10, 15, 20 and 30 min by detecting high, medium and low concen-
trations of NT-proBNP samples. The results would be judged from the
ﬂuorescence intensity of each concentration, the reaction repeatability
and integrity. As shown in Fig. 6, the ﬂuorescence intensity of the
n=131
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Table 3
Comparison of the detection of serum samples to the whole blood and plasma samples.
Pair Sample N Mean ± SD (pg ml−1) t p
Pair1 Serum 50 5719.37 ± 7183.61 1.411 0.164
Whole blood 50 5662.54 ± 7123.81
Pair2 Serum 50 5719.37 ± 7183.61 −0.611 0.544
Plasma 50 5741.19 ± 7215.29
p b 0.05, statistically signiﬁcant difference.
Table 1
Inter-assay and intra-assay reproducibility (precision of the assay).
Spiked
(pg ml−1)
Inter-assay precision
(n = 20)
Intra-assay precision
(n = 20)
Mean ± SD
(pg ml−1)
CV
(%)
Mean ± SD
(pg ml−1)
CV
(%)
500 503.2 ± 45.58 9.1 503.2 ± 47.93 9.5
5000 5031.7 ± 483.93 9.6 5071.3 ± 483.90 9.6
6 H. Li et al. / Sensing and Bio-Sensing Research 11 (2016) 1–7three samples increased along with reaction time and did not achieve
equilibrium before 10 min of reaction, and longer reaction times
did not obviously change theﬂuorescence intensity, the reaction repeat-
ability and integrity. Considering the time consumed, 10 min was se-
lected as the most suitable reaction time for the following experiments.
3.6. Linear range and the analytical sensitivity
Under optimized experimental conditions, a series of NT-proBNP
standards with different concentrations (0, 200, 3250, 6500, 9750,
13,000, 16,250, 19,500, 22,750, 26,000, 29,250 and 32,500 pg ml−1)
were continuously measured four times for each concentration, and
the calibration curve for NT-proBNP was illustrated in Fig. 7. The results
were ﬁt by SPSS13.0 to a regression curve. Under optimal conditions,
the calibration curve for NT-proBNP was ﬁtted by the equation: y =
0.957x+ 373 with a correlation coefﬁcient of 0.998. It showed a linear
range from 200 to 26,000 pg ml−1. The blank sample was repeatedly
measured 20 times and calculated the mean and standard deviation.
The resulting mean plus two standard deviations were deﬁned as the
limit of detection, which was 47 pg ml−1. These results indicated that
the sensitivity reached permitted determination of very low levels of
NT-proBNP. And most important of all, the entire analysis can be com-
pleted within 15 min. Thus, the results suggested that the ﬂuorescent
immunochromatographic assay possessed high sensitivity and wider
detection range and could be used as a potential clinical application
for the detection of NT-proBNP.
3.7. Precision and accuracy of the assay
Precision of the assay was evaluated by intra-assay and inter-assay
coefﬁcients of variation (CV) according to the CLSI EP5-A2 guideline
[31]. Brieﬂy, we analyzed two separate runs with two test samples of
high and low concentration of NT-proBNP daily, and the samples were
tested in duplicate per run, two separate runs per day with an interval
of at least 2 h. The experiment lasted for 20 days. The CVs at the concen-
trations of 500 pgml−1 and 5000 pgml−1 were 9.1% and 9.6% for intra-
assay, 9.5% and 9.6% for inter-assay. Both the intra-assay and the inter-
assay CVs were lower than 10%, and the results are within the criteria
recommended by the CLSI guideline (Table 1). The accuracy of the
assay was estimated by adding the samples of NT-proBNP at the con-
centrations of 5000 pgml−1 and 10,000 pgml−1 into the given amount
of NT-proBNP standard (1000 pg ml−1) at various analyte levels. All of
the samples were measured three times and then the mean recoveriesTable 2
Recovery (accuracy of the assay).
Original
(pg ml−1)
Spiked
(pg ml−1)
Observed Mean ± SD
(pg ml−1)
Recovery
(%)
1000 5000 5984.13 ± 553.35 97.5
1000 10,000 11,023.83 ± 773.13 99.1were calculated. As shown in Table 2, the recoveries of the analyte
were 97.5% and 99.1%. Therefore, the precision and accuracy of the
assay established in our study were acceptable.3.8. Comparison of the detection of serum samples to the whole blood and
plasma samples
To further evaluate the performance of the new
immunochromatographic assay, 50 cases of serum, plasma and whole
blood samples frompatientswere detected respectively. And the results
were analyzed by paired-samples t-test. As shown in Table 3, for pair 1
and pair 2, the comparative analysis of serum samples to whole blood
and plasma samples showed no signiﬁcant difference (p = 0.164 or
p = 0.544). This ﬁnding suggested that the immunochromatographic
assay could serve for clinical determination of NT-proBNP in human
serum, plasma and whole blood.3.9. Clinical application of the assay
The feasibility of the immunochromatographic assay for clinical appli-
cation was further investigated by analyzing 131 clinical serum samples
from patients. And the results were compared with those detected by a
commercial CLIA kit. Linear regression analysis was shown in Fig. 8. The
data revealed a good correlation between the immunochromatographic
method and CLIA with a correlation coefﬁcient of 0.978. The equation of
the regression curvewas y=0.973x+121.2,where x represents the con-
centration of NT-proBNP calculated by our immunochromatographic
method and y represents the concentration of NT-proBNP calculated by
the CLIA method. The results indicate that the immunochromatographic
assay has good potential clinical application for the detection of NT-
proBNP.0 5,000 10,000 15,000 20,000 25,000 30,000
5.0×103
0
The fluorescent immunochromatographic method (pg/ml)
CL
I
Fig. 8. Comparison between the ﬂuorescent immunochromatographic method and CLIA.
The comparison was made by using 131 clinical serum samples. The data revealed a
good correlation between the proposed method and CLIA with a correlation coefﬁcient
of 0.978.
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In conclusion, a novel ﬂuorescent immunochromatographic method
for detecting NT-proBNP in human serum was successfully developed.
The method applied a ﬂuorescent protein modiﬁed by streptavidin as a
tracer to conjugate the biotin-labeled anti-NT-proBNP antibody on the
conjugation pad to facilitate the detection of NT-proBNP in human
serum samples. This assay platform revealed several advantages com-
pared with conventional methods, such as higher sensitivity, higher efﬁ-
ciency, broader dynamic assay ranges and less consumption of reagents.
Furthermore, the assay showed good properties for detection of NT-
proBNP with acceptable precision and accuracy. And it also displayed
good correlation with CLIA kit. This immunosensor could be developed
into commercially available ﬂuorescent immunochromatographic kits
for the clinical detection of NT-proBNP or other biomarkers, and its celer-
ity provides highly promising for in-ﬁeld and point-of-care diagnosis es-
pecially during emergency events.
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